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SUMMARY
Many patients with type 1 diabetes (T1D) have resid-
ual b cells producing small amounts of C-peptide
long after disease onset but develop an inadequate
glucagon response to hypoglycemia following T1D
diagnosis. The features of these residual b cells
and a cells in the islet endocrine compartment are
largely unknown, due to the difficulty of comprehen-
sive investigation. By studying the T1D pancreas
and isolated islets, we show that remnant b cells
appeared tomaintain several aspects of regulated in-
sulin secretion. However, the function of T1D a cells
was markedly reduced, and these cells had alter-
ations in transcription factors constituting a and b
cell identity. In the native pancreas and after placing
the T1D islets into a non-autoimmune, normoglyce-
mic in vivo environment, there was no evidence of
a-to-b cell conversion. These results suggest an
explanation for the disordered T1D counterregula-
tory glucagon response to hypoglycemia.
INTRODUCTION
The events related to type 1 diabetes (T1D) pathophysiology in
humans are poorly defined. For example, we do not under-
stand the initiating trigger for T1D, how b cell loss proceeds,
whether the loss is inevitable or can be abrogated, or the po-
tential for residual b cell recovery. The long-standing view of
T1D pathogenesis was that autoimmune b cell destruction re-
sulted in complete loss of pancreatic insulin secretion. The
improved sensitivity of C-peptide detection as well as studies
using pancreatic specimens have recently led to the realiza-
tion that many individuals with T1D have insulin-secreting
cells, even 50 years after diagnosis (Keenan et al., 2010;
Oram et al., 2014). Additionally, little is known about the prop-
erties of the glucagon-producing a cells in the T1D pancreas
and whether they share the plasticity recently described in
mouse models of profound b cell loss (Chera et al., 2014;
Thorel et al., 2010). Moreover, it is unclear why T1D a cells
have impaired glucagon secretion (Bolli et al., 1983; Gerich
et al., 1973; Sherr et al., 2014), which contributes to hypogly-
cemia susceptibility.
To comprehensively define the functional and molecular
properties of T1D islets, we used an approach that allows
study of the pancreas and isolated islets from the same organ
donor. Our findings show that remnant b cells appeared to
maintain several features of regulated insulin secretion. In
contrast, glucagon secretion was significantly compromised,
and the levels of essential a cell transcription factors and
their downstream targets involved in a cell electrical activity
were reduced. Moreover, an important b-cell-enriched tran-
scription factor was misexpressed in T1D a cells. These re-
sults provide insight into the functional and molecular profile
of a cells in T1D.
RESULTS
Procurement of Pancreatic Islets and Tissue from the
Same Organ Donor Allows for Multifaceted Phenotypic
Analysis of T1D Islets
Our methodology for islet isolation and tissue procurement from
the same pancreas allowed coupling of islet functional and
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molecular analysis with histological assessment of islets in the
native organ (Figure S1A). In this way, we were able to study 5
donors with recent-onset T1D (<10 years of T1D duration) and
3 donors with long-standing T1D (>10 years of T1D duration)
receiving continuous insulin therapy compared to the appro-
priate non-diabetic controls (Tables 1 and S1). Experimental ap-
proaches used for analysis of each T1D donor are indicated in
Table 1 and labeled accordingly in figure legends. Due to clinical
heterogeneity of T1D, we confirmed disease status by DNA
sequencing (Sanyoura et al., 2018) as described in the Supple-
mental Experimental Procedures. DNA sequencing covering
coding regions and splice junctions of 148 genes associated
with monogenic diabetes did not detect variants associated
with monogenic diabetes (Alkorta-Aranburu et al., 2016;
Table S2). By flow cytometry analysis, recent-onset T1D islets
contained 7-fold more a cells than b cells, and the b cell fraction
was reduced approximately 6-fold compared to normal islets
(Blodgett et al., 2015; Figures S1B–S1D).
T1D b Cells Have Regulated Insulin Secretion
and Express Key Transcriptional Regulators
Next, we analyzed the secretory function of the T1D islets in a
dynamic cell perifusion system and compared it with islets
from normal donors (Kayton et al., 2015). We found that the
few remaining T1D b cells responded to glucose, cyclic AMP
(cAMP)-evoked stimulation, and KCl-mediated depolarization
with a similar pattern as controls (Figures 1A and 1B). The
biphasic glucose-stimulated insulin secretion in islets at T1D
onset was also shown recently by Krogvold and colleagues
(Krogvold et al., 2015). As expected, insulin secretion by T1D is-
lets was diminished when normalized to overall islet cell volume
(expressed in islet equivalents [IEQs]; Figure 1A) due to the
greatly reduced b cell number (Figure S1C). However, insulin
secretion normalized to islet insulin content (reflecting b cell
number) by T1D islets nearly overlapped in terms of magnitude
with the secretory response of controls (Figure 1B). Consistent
with flow cytometry data in Figure S1C, the T1D b cell population
was 4- to 6-fold less than in control islets when adjusted to
islet insulin content (Figure 1C). Furthermore, the expression of
transcription factors critical for b cell identity PDX1 (Gao et al.,
2014) and NKX6.1 (Taylor et al., 2013) was not changed in
either isolated T1D islets (Figure 1D) or by protein analysis of
the native pancreatic tissue (Figures 1E, 1F, and S2). Even in
the 58-year-old T1D donor with long-standing T1D, these tran-
scription factors were expressed in rare insulin+ cells found scat-
tered in the exocrine parenchyma (Figures 1E, 1F, and S2). How-
ever,MAFA (Guo et al., 2013), a transcription factor known to be
required for murine b cell maturation, was reduced in the T1D
islet (Figure 1D), and there were fewer NKX2.2-expressing T1D
b cells compared to controls (Figures 1G and S2), even though
islet NKX2-2 mRNA was unchanged (Figure 1D). These studies
allowed us to directly access multiple pathways of insulin secre-
tion and suggest that the T1D b cells appear to maintain several
functional features of normal b cells, supporting the notion that
T1D is a disease primarily of b cell loss. Due to very few T1D b
cells available for deeper analyses, we focused our efforts on
comprehensive characterization of the most abundant endo-
crine cell type in T1D islets, the a cell (Figure S1C).
T1D a Cells Are Functionally Impaired and Have Altered
Expression of Transcription FactorsConstituting a andb
Cell Identity
Surprisingly, in spite of T1D islets containing 2-fold more a cells
than normal islets (Figure S1C), their glucagon secretion was not
significantly increased compared to controls when normalized to
overall islet cell volume (expressed as IEQs; Figure 2A). The
response was reduced when normalized to islet glucagon con-
tent (Figures 2B and 2C) and lacked the appropriate increase
at low glucose following 30-min high glucose inhibition (Fig-
ure 2B, inset). Marchetti and colleagues (Marchetti et al., 2000)
observed a similar defect in glucagon secretion in islets isolated
from a single T1D donor 8 months after the disease onset. These





(Years) Ethnicity/Race Gender BMI
Cause
of Death High-risk HLAa AutoAb
C-Peptide
(ng/mL) HbA1Cb
1 12 3 Caucasian F 26.6 anoxia DR3, DQ2 mIAA 0.05 9.8
2 13 5 Caucasian M 19.1 anoxia DR4, DQ2, DQ8 IA2A, mIAA <0.02 NA
3 nPOD
case no. 6342
14 2 Caucasian F 24.3 anoxia DR4 IA2A, mIAA 0.26 9.2
4 20 7 Caucasian M 25.5 anoxia DR4, DQ2, DQ8 IA2A 0.43 NA
5 nPOD
case no. 6323
22 6 Caucasian F 24.7 anoxia DR3, DR4, DQ2 GADA, IA2A <0.02 6.6
6 27 17 Caucasian M 18.5 anoxia DR4, DQ2, DQ8 ND <0.02 NA
7 30 20 Caucasian M 29.8 anoxia DR4, DQ8 ND <0.02 NA
8 58 31 Caucasian M 21.7 anoxia DR4 NA NA 8.8
The nature of T1D pancreas, organ scarcity, and logistics of organ procurement and processing precluded us from collecting the entire dataset on each
T1D donor. Perifusion, donors nos. 1, 3, 4, and 5; qRT-PCR, donors nos. 1, 4, and 5; islet endocrine cell composition by FACS, donors nos. 1, 4, 5, and
8; histology, donors nos. 1, 2, 5, and 8; islet transplantation, donors nos. 1, 5, and 8; a cell purification and RNA sequencing, donors nos. 3, 6, and 7.
AutoAb, autoantibodies; GADA, glutamic acid decarboxylase autoantibody; HbA1C, hemoglobin A1C; IA2A, autoantibody to transmembrane protein
of the protein tyrosine phosphatase family; mIAA, insulin autoantibody; NA, not available; ND, non-detectable.
aHLA typing provided by Organ Procurement Organization.
bHbA1C collected from donor’s redacted medical chart.
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Figure 1. T1D b Cells in Recent-Onset T1D Retain Secretory Properties and Gene Expression Pattern Similar to Normal b Cells
(A and B) Insulin secretion was assessed in islets isolated fromdonorswith recent-onset T1D (n = 4; ages 12–22 years; donors nos. 1, 3, 4, and 5) and compared to
normal controls (n = 7; ages 7–21 years); G 5.6–5.6mMglucose, G 16.7–16.7mMglucose, G 16.7 + IBMX 100–16.7mMglucose + 100 mM isobutylmethylxanthine
(IBMX), G 1.7 + Epi 1–1.7 mM glucose + 1 mM epinephrine, KCl 20–20 mM potassium chloride.
(A) Insulin secretion normalized to overall islet cell volume (expressed as islet equivalents [IEQs]); ****p < 0.0001.
(B) Insulin secretion normalized to islet insulin content; ***p = 0.0005. Data in (A) and (B) were compared by two-way ANOVA.
(C) Insulin content of control (3.873 ± 0.763 ng/IEQ) and T1D islets (1.131 ± 0.660 ng/IEQ); p = 0.0394; data are represented as mean ± SEM.
(D) Expression of b-cell-enriched transcription factors by qRT-PCR in whole T1D islets (n = 3 donors; ages 12–22 years; donors nos. 1, 4, and 5) and controls (n = 3
donors; ages 11–29 years) was normalized to endogenous control and INS expression; ***p < 0.0007.
(E–G) Expression of b-cell-enriched transcription factors in the native pancreatic tissue from donors with recent-onset T1D (n = 2; ages 12–22 years; donors nos. 1
and 5) was compared to 58-year-old donor with 31 years of T1D duration (donor no. 8) and controls (n = 7; ages 8–55 years). The pancreas of 58-year-old T1D
(legend continued on next page)
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functional changes in T1D a cells were accompanied by reduced
mRNA expression of two bona fide a cell regulators ARX (Court-
ney et al., 2013) and MAFB (Guo et al., 2013) in isolated islets
(Figure 2D). Notably, histological analysis of native tissues further
revealed that most a cells from T1D donors did not express
MAFB and ARX (Figures 2E, 2F, and S3) but did express low
levels of NKX6.1 (Figures 2G and S3), which is normally only
found in b cells (Figures 1G and S2). A similar pattern has been
seen in a mouse model with extreme b cell loss (Chera et al.,
2014; Thorel et al., 2010). To test whether there was evidence
of a-to-b cell conversion in the T1D donor pancreas, we
searched for, but did not find, islet cells co-expressing insulin
and glucagon (data not shown). This observation differs from
the recently described a-to-b cell conversion in a mouse model
of 99% b cell loss (Chera et al., 2014; Thorel et al., 2010).
Non-autoimmune, Normoglycemic Environment Does
Not Promote Conversion of T1D a Cells into b Cells
To determinewhether human T1D a cells following extreme b cell
loss can give rise to b cells when placed in a normoglycemic,
non-autoimmune environment, we transplanted islets from the
same T1D donors into immunodeficient Nod-SCID-IL2Rgnull
(NSG) mice (Brissova et al., 2014; Figure 3A). After one-month
engraftment, mice were treated with either PBS or exendin-4
(Dai et al., 2017), a GLP-1 analog reported to promote b cell
maturation or proliferation for an additional 1 month. At the end
of the treatment, in vivo insulin secretion was stimulated by a
bolus of high glucose and arginine. Although a species-specific
assay readily detected a rise in mouse plasma insulin levels,
human insulin was undetectable (data not shown), indicating
the absence of functional human b cells in T1D islet grafts.
Similar to native tissue, graft immunocytochemistry showed
that b cells were very rare and did not detect insulin/glucagon
co-expression (Figure 3B; data not shown). Because there
were no significant phenotypic differences between PBS- and
exendin-4-treated groups, these treatment groups were com-
bined to assess a cell transcription factor expression. After
transplantation, the number of a cells expressing ARX in T1D
islet grafts was greater (Figure 3D) with a decrease in the number
of NKX6.1+ a cells (Figure 3E) compared to a cells in the native
T1D pancreas, suggesting that the normoglycemic, non-autoim-
mune environment allowed for partial recovery of a cell identity
marker expression.
Genes Critical to a Cell Identity and Function Are
Differentially Expressed between T1D and Control a
Cells
T1D and control islet a cells were purified by fluorescence-acti-
vated cell sorting (FACS) (Figure S4A). RNA-sequencing analysis
(RNA-seq) performed on these cells indicated significant differ-
ences in the gene expression profiles (Figures 4A, 4B, and
S4B). Ingenuity pathway analysis (IPA) and Gene Ontology
(GO) term analysis (Tables S3 and S4; Figures S4C and S4D)
identified differences in processes associated with protein syn-
thesis and handling, immune-activated signaling, and cell stress
response pathways. Specifically, T1D a cells had increased
expression of genes important in the unfolded protein response
and formation of tight and adhesive junctions. Conversely, T1D a
cells had significantly reduced expression of genes recently
identified by single-cell RNA-seq as a cell enriched, such as
KLHL41, LOXL4, and PTGER3 (Muraro et al., 2016; Segerstolpe
et al., 2016; Figure 4C). Our RNA-seq analysis further confirmed
dysregulated expression of several islet-enriched transcription
factors in T1D a cells, which we initially detected by RT-PCR
in whole islets and at a protein level in pancreatic tissues
(MAFB, ARX, and NKX6-1; Figures 2D–2G and 4C). Among
islet-enriched transcription factors, RFX6, which lies upstream
of MAFB, ARX, and NKX6-1 in endocrine cell differentiation
(Piccand et al., 2014; Smith et al., 2010), had the most reduced
expression (7.2-fold). In mature mouse and human b cells,
RFX6 directly controls expression of P/Q and L-type voltage-
gated calcium channels (CACNA1A,CACNA1C, andCACNA1D)
and the KATP channel subunit sulfonylurea receptor 1 (ABCC8)
(Chandra et al., 2014; Piccand et al., 2014; Figure 4C) that asso-
ciates with Kir6.x pore-forming subunits (Winkler et al., 2009).
T1D a cells also had altered expression of potassium and sodium
ion channels, vesicle trafficking proteins, and cAMP signaling
molecules, which collectively point to altered T1D a cell electrical
activity and impaired glucagon exocytosis (Figure 4D).
DISCUSSION
These results show the utility and advantages of an experimental
approach that studies the pancreatic tissue and isolated islets
from the same T1D individual and incorporates the in vitro and
in vivo analysis of islets removed from the autoimmune, hyper-
glycemic environment. This approach also allowed us to directly
test multiple pathways of hormone secretion and uncouple ef-
fects of decreased b cell mass and b cell dysfunction not
possible in clinical studies in vivo. We found that the rare b cells
in the pancreas present not only in recent-onset T1D but also
many years after T1D diagnosis maintained features of regulated
insulin secretion and/or produced key transcriptional regulators
known to play a critical role in the maintenance of b cell fate and
function. In contrast, T1D a cells, while highly abundant, were
functionally impaired. Impaired glucagon secretion by T1D islets
was associated with altered expression of multiple nuclear reg-
ulators (e.g., ARX, MAFB, and RFX6) and their downstream tar-
gets, suggesting that these changes directly and indirectly
impact glucagon secretory pathways by altering expression of
potassium and sodium ion channels, vesicle trafficking proteins,
and cAMP signaling molecules. Abnormal glucagon secretion is
a common complication of T1D, including impaired counterregu-
latory response of glucagon to hypoglycemia (Gerich et al., 1973)
donor did not have any insulin+ islets; only rare b cells were found in exocrine parenchyma. T1D b cells (n = 3 donors; ages 12–58 years; donors nos. 1, 5, and 8)
had normal expression of b-cell-enriched transcription factors PDX1 (E) and NKX6.1 (F) but decreased expression of NKX2.2 (G) compared to controls (n = 7
donors; ages 8–55 years); ****p < 0.0001; ns, not significant.
Data in (C)–(G) were compared by two-tailed Student’s t test. Data in (A)–(G) are shown as mean ± SEM. The scale bar in (E) represents 10 mm and also cor-
responds to (F) and (G). See also Figures S1 and S2.
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Figure 2. T1D a Cells in Recent-Onset T1D Have Reduced Glucagon Secretion and Dysregulated Gene Expression
The same sets of islets shown in Figures 1A and 1Bwere simultaneously analyzed for glucagon secretion. The same non-diabetic controls were used as Figure 1.
The labeling of islet stimuli is identical to that in Figure 1.
(A) Glucagon secretion normalized to overall islet cell volume (expressed as IEQs); p = 0.2470.
(B) Glucagon secretion normalized to islet glucagon content; ****p < 0.0001. Data in (A) and (B) were compared by two-way ANOVA. Inset shows mean glucagon
response to low glucose following the 30-min inhibition with high glucose.
(C) Glucagon content in control (206 ± 62 pg/IEQ) and T1D islets (362 ± 149 pg/IEQ); p = 0.2831; data are represented as mean ± SEM.
(D) Expression of a-cell-enriched factors by qRT-PCR inwhole T1D islets (n = 3 donors; ages 12–22 years; donors nos. 1, 4, and 5) and controls (n = 3 donors; ages
11–29 years) was normalized to endogenous control and GCG expression; ****p < 0.0001; *p = 0.0184.
(legend continued on next page)
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and an inappropriate rise in circulating glucagon in response to a
mixed meal challenge (Sherr et al., 2014). Defects in neural
glucose sensing, impaired islet innervation, or intra-islet insulin
deficiency have been proposed to explain these abnormalities
in glucagon secretion (Mundinger et al., 2016). The current anal-
ysis provides a new explanation and molecular mechanism for
the dysregulated glucagon secretion in T1D, namely an intrinsic
a cell defect (Figure 4D). Our observation that the changes in a
cell gene expression partially resolved when T1D islets were
transplanted into a normoglycemic, non-autoimmune environ-
ment suggests that interventions might be developed to improve
a cell gene expression and glucagon secretion in T1D.
These data provide insight and raise important questions
about the molecular and functional changes in human T1D
a cells. After massive b cell loss in mice, b cells can be
gradually and partially replenished by a sustained a-to-b
cell reprogramming (Chera et al., 2014; Thorel et al., 2010).
Unlike in mice, the current analysis did not identify cells co-
expressing insulin and glucagon in the native pancreas or
after transplantation into a normoglycemic, non-autoimmune
environment, further supporting the notion that a-to-b cell
conversion in humans is a very rare event (Chakravarthy
et al., 2017). Our findings do suggest that T1D a cells have
reduced key molecular regulators (ARX and MAFB) and ex-
press a transcription factor, NKX6.1, that is usually b cell
specific, raising the possibility of partial change toward a b
cell phenotype. Perhaps an additional stimulus or multiple
stimuli may be required for human a cell reprogramming.
Lineage-tracing studies of human a cells are needed to
investigate the plasticity of human a cells.
These results stimulate a number of questions about the mo-
lecular and cellular changes in T1D islets. Are the a cell
changes the result of the autoimmune attack on the b cells
also affecting a cells, the lack of a cell-b cell contact, the dia-
betic milieu of hyperglycemia, or reduced intra-islet insulin?
Have the remnant b cells, which have a number of features of
normal b cells, somehow escaped the autoimmunity; do they
comprise a specific subset of b cells (Dorrell et al., 2016); or
do they represent an incomplete regenerative attempt, arising
via de novo neogenesis from facultative pancreas progenitors
(Xu et al., 2008), b replication (Brissova et al., 2014; Cano
et al., 2008; Nir et al., 2007), and/or transdifferentiation of acinar
cells (Zhou et al., 2008) or other islet endocrine cell types, such
as a cells (Chera et al., 2014; Thorel et al., 2010)? Additional
studies of isolated T1D islets and T1D pancreatic tissue are
needed to better understand the phenotype and possible het-
erogeneity of T1D a and b cells.
EXPERIMENTAL PROCEDURES
Further details and an outline of resources used in this work can be found in
Supplemental Experimental Procedures (Resources Table).
Animals
Immunodeficient 10- to 12-week-old NSG male mice were used for human
islet transplantation studies (Brissova et al., 2014; Dai et al., 2016). Animals
were maintained by Vanderbilt Division of Animal Care in group housing in
sterile containers within a pathogen-free barrier facility housed with a 12 hr
light/12 hr dark cycle and access to free water and standard rodent chow.
All animal procedures were approved from by the Vanderbilt Institutional
Animal Care and Use Committees.
Primary Cell Cultures
Primary human islets were cultured in CMRL 1066 media (5.5 mM glucose,
10% FBS, 1% Pen/Strep, and 2 mM L-glutamine) in 5% CO2 at 37
C for
24–72 hr prior to reported studies (Brissova et al., 2014; Dai et al., 2016). No
cell lines were used in this study.
Human Subjects
Pancreata and islets from normal and T1D donors were obtained through a
partnership with the International Institute for Advancement of Medicine
(IIAM), National Disease Research Interchange (NDRI), Integrated Islet
Distribution Program (IIDP), and Network for Pancreatic Organ Donors with
Diabetes (nPOD). Most pancreata from normal donors were processed
either for islet isolation (Balamurugan et al., 2003) or histological analysis
(described below and Table S1). In most T1D pancreatic organs, islets and
tissue specimens were procured from the same organ. For a number of
controls, human islets were obtained through IIDP (Table S1). Donor
demographic information and phenotype of T1D donors is summarized in
Table 1. The Vanderbilt University Institutional Review Board declared
studies on de-identified human pancreatic specimens do not qualify as
human subject research.
Human Pancreatic Islet Procurement
Pancreata from normal juvenile and T1D donors were received within 18 hr
from cold clamp and maintained in cold preservation solution on ice until
processing. Pancreas was then cleaned from connective tissue and fat,
measured, and weighed. Prior to islet isolation, multiple cross-sectional
slices of pancreas with 2- to 3-mm thickness were obtained from the
head, body, and distal tail (Figure S1A). Pancreatic slices were further
divided into four quadrants and then either snap frozen or processed for
cryosections. Tissue specimens processed for cryosections were fixed in
0.1 M PBS containing 4% paraformaldehyde (Electron Microscopy
Sciences) for 3 hr on ice with mild agitation, washed in four changes of
0.1 M PBS over 2 hr, equilibrated in 30% sucrose/0.01 M PBS overnight,
and embedded in Tissue-Plus O.C.T. compound (Fisher Scientific). Pancre-
atic organs were processed for islet isolation using an approach previously
described (Balamurugan et al., 2003). Briefly, depending on the size of
pancreatic duct, 18G or 22G catheters were inserted into the main pancre-
atic duct (one catheter toward head and the other one toward tail). Acces-
sory duct and main pancreatic duct were clamped at the points where
sections were collected to prevent leakage of collagenase solution during
infusion. Collagenase solution consisting of collagenase NB1 (1,600 U/isola-
tion; Crescent Chemical), neutral protease NB1 (200 U/isolation; Crescent
Chemical), and DNase I (12,000 U/isolation; Worthington Biochemical
Corporation) was pre-warmed to 28C and delivered intraductally using a
Rajotte’s perfusion system and then maintained at 37C for approximately
20 min. The inflated tissue was then transferred to a Ricordi’s chamber
apparatus for combined mechanical and enzymatic digestion, which was
maintained at 36C for 5–15 min prior to warm and cold collection. The
digest was incubated in cold RPMI media (Mediatech) supplemented with
heat-inactivated 10% fetal calf serum (Life Technologies) for 1 hr on ice.
(E–G) Analysis of native pancreatic tissue for expression of islet-enriched transcription factors. T1D a cells (n = 4 donors; ages 12–58 years; donors nos. 1, 2, 5,
and 8) expressed b cell marker NKX6.1 (G) and lost bona fide a cell markers MAFB (E) and ARX (F) in most T1D a cells compared to controls (n = 7 donors; ages
8–55 years); ****p < 0.0001.
Data in (C)–(G) were compared by two-tailed Student’s t test. Data in (A)–(G) are shown as mean ± SEM. The scale bar in (E) represents 10 mm and also cor-
responds to (F) and (G). See also Figures S1 and S3.
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If post-digestion tissue pellet was larger than 2 mL and islets were distin-
guishable from exocrine tissue by Dithizone staining (Sigma), a purification
step consisting of density gradient (Biocoll; Cedarlane) centrifugation on a
COBE 2991 Cell Processor (Gambro-Terumo) was used to separate islets
from exocrine tissue. Islets were re-suspended in CMRL 1066 medium
(Mediatech) supplemented with 10% heat-inactivated fetal calf serum
(Life Technologies), 100 units/mL penicillin/0.1 mg/mL streptomycin (Life
Technologies), and 2 mmol/L L-glutamine (Life Technologies). On average,
islet-enriched fraction contained from 30,000 (T1D pancreas) to 90,000
IEQs (normal pancreas) with 25%–50% purity. Islets were cultured for
12–24 hr and then shipped from Pittsburgh to Vanderbilt University and/or
University of Massachusetts for further analysis following shipping
protocols developed by the Integrated Islet Distribution Program (IIDP).
Subsequent assays with isolated islets were set up within 24–48 hr of islet
arrival.
Statistical Analysis
To compare global differences in perifusion outcomes in T1D donors and con-
trols, two-way ANOVA with Sidak’s multiple comparisons test was used. Data
were expressed as mean ± SEM. Two-tailed Student’s t test was used for
Figure 3. T1D a Cells Do Not Show Evidence of a-to-b Cell Reprogramming in Normoglycemic, Non-autoimmune Environment
(A) Islets from donors with recent-onset and long-standing T1D (n = 3 donors; 12–58 years; donors nos. 1, 5, and 8) depicted in Figures 1 and 2 were transplanted
into NSGmice. After 1-month engraftment, mice were treated with either PBS or Ex-4 for an additional 1 month. Representative images of islet grafts are from the
12-year-old individual with 3-year T1D duration (donor no. 1). In control and T1D columns, regions denoted by the dashed line in images on the left (B)–(E) (scale
bar in B is 50 mm) are displayed on the right (scale bar is 10 mm).
(B) Insulin (INS) and glucagon (GCG) double-positive cells were not detected in either type of T1D islet grafts (PBS or Ex-4).
(C–E) As there were no phenotypic differences between PBS and Ex-4 treatment groups, representative images were taken from both cohorts and analyzed for a
cell transcription factor expression. Change in number of GCG+ cells expressing MAFB (C), ARX (D), and NKX6.1 (E) in transplanted T1D islets (TX) relative to
donor’s native pancreas (Panc) is shown. ****p < 0.0001; ns, not significant.
Data in (C)–(E) are shown as mean ± SEM and were compared by two-tailed Student’s t test.
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Figure 4. Genes Critical to a Cell Function Are Differentially Expressed in T1D a Cells
Transcriptome by RNA-sequencing analysis of purified human a cells from T1D donors (n = 3; ages 14–30 years; donors nos. 3, 6, and 7) and controls (n = 5; ages
26–55 years).
(A) Principal-component analysis (PCA) plot shows clustering of a cell samples from control and T1D donors.
(B) Heatmap of the pairwise correlation between all samples based on the Spearman correlation coefficient. Perfect correlation is indicated by 1.
(C) Genes associated with a cell identity and function are significantly downregulated in the T1D a cells with increased expression of stress response factors and
cell-cell contact proteins. Vertical dotted lines represent point of significance for fold change (FC) = 1.53 threshold analysis; p < 0.05 for all values shown.
(legend continued on next page)
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analysis of statistical significance for two-group comparisons between T1D
donors and controls. A p value less than 0.05 was considered significant. Sta-
tistical analysis was performed using GraphPad Prism software. Statistical de-
tails of experiments are described in the figure legends, Results section, and
Supplemental Experimental Procedures.
DATA AND SOFTWARE AVAILABILITY
The accession number for the sequencing data reported in this paper is GEO:
GSE106148.
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Supplemental information includes Supplemental Experimental Procedures,
four figures, and four tables and can be found with this article online at
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Contact  for  reagent  and  resource  sharing  
Further  information  and  requests  for  resources  and  reagents  should  be  directed  to  and  will  be  




DNA  samples  were  sequenced  using  a  custom  designed  next-­generation  sequencing  (NGS)  
targeted  panel  that  includes  148  genes  implicated  in  monogenic  forms  of  diabetes  (neonatal  
diabetes  and  MODY),  insulin  resistance,  lipodystrophy,  obesity,  rare  syndromic  forms  of  
diabetes,  and  diabetes  candidate  genes  (Alkorta-­Aranburu  et  al.,  2016).  The  targeted  NGS  
approach  was  based  on  the  SureSelect  enrichment  (Agilent  Technologies)  protocol  followed  by  
MiSeq  Illumina  NGS.  Data  quality  was  assessed  using  FastQC.  Variants  were  called  using  The  
Genome  Analysis  Toolkit  (GATK)  HaploTypeCaller  v3.3  and  assigned  to  the  transcripts  of  
interest.  Variants  were  then  annotated  in  regards  to  their  positions  in  transcripts  of  interest,  
position  relative  to  the  coding  sequence,  consequence  for  the  protein  or  mRNA  and  a  collection  
of  direct  and  indirect  evidentiary  tools  and  databases  including  NCBI  dbSNP,  1000  Genomes  
Project,  Exome  Sequencing  Project  (ESP),  GERP,  Conseq,  PolyPhen-­2,  SIFT  and  the  Human  
Gene  Mutation  Database  (HGMD).  All  variants  were  interpreted  according  to  the  guidelines  of  
the  American  College  of  Medical  Genetics.  All  likely  pathogenic  variants  identified  by  NGS  were  
confirmed  by  Sanger  sequencing.  
  
Measurement  of  endocrine  cell  populations    
Islet  dissociation  and  intracellular  antibody  staining  used  a  previously  described  protocol  
(Blodgett  et  al.,  2015).  Anti-­insulin  (Gallus  Immunotech),  anti-­chicken  allophycocyanin,  (Jackson  
ImmunoResearch),  anti-­glucagon  (Sigma-­Aldrich)  conjugated  with  Zenon  Pacific  Blue  
(Invitrogen),  and  anti-­somatostatin  (LSBio)  conjugated  with  Zenon  Alexa  Fluor  488  (Invitrogen)  
were  used  to  stain  β,  α,  and  δ  cells,  respectively  (Resources  Table).  Dissociated  islet  cell  
preparations  were  analyzed  using  a  BD  Biosciences  FACS  Aria  II  Cell  Sorter  (University  of  
Massachusetts  Medical  School  Flow  Core  Laboratory).  Cellular  debris  was  eliminated  from  islet  
preparations  using  a  forward  scatter  versus  side  scatter  size  gate.    
  
Assessment  of  pancreatic  islet  function  in  vitro  
Function  of  islets  from  T1D  donors  and  normal  controls  (Tables  1  and  S1)  was  studied  in  a  
dynamic  cell  perifusion  system  at  a  perifusate  flow  rate  of  1  mL/min  (Kayton  et  al.,  2015).  The  
effluent  was  collected  at  3-­minute  intervals  using  an  automatic  fraction  collector.  Insulin  and  
glucagon  concentrations  in  each  perifusion  fraction  and  islet  extracts  were  measured  by  
radioimmunoassay  (Millipore).    
  
qRT-­PCR  of  isolated  pancreatic  islets  
Quantitative  reverse  transcription  polymerase  chain  reaction  (qRT-­PCR)  was  performed  using  
the  primer-­probe  approach  from  Applied  Biosystems  (Life  Technologies)  with  18S  and  ACTB  
endogenous  controls  using  Minimum  Information  for  Publication  of  Quantitative  Real-­Time  PCR  
Experiments  (MIQE)  guidelines  as  described  (Brissova  et  al.,  2014).  All  primers  are  listed  in  
Resources  Table.  Gene  expression  in  recent-­onset  T1D  donors  was  compared  to  normal  
controls  (Tables  1  and  S1).  We  were  able  to  detect  INS  mRNA  in  T1D  islets  by  RT-­PCR  and  




  α  cell  sorting  by  flow  cytometry  for  RNA-­sequencing  
Human  islets  were  dispersed  using  a  modified  protocol  as  described  previously  (Aamodt  et  al.,  
2016).  Briefly,  0.025%  trypsin  was  used  to  disperse  cells  and  reaction  was  quenched  with  
modified  RPMI  medium  (10%  FBS,  1%  Penn/Strep,  5  mM  glucose).    Cells  were  washed  in  the  
same  medium  and  counted  on  a  hemocytometer,  then  transferred  to  FACS  buffer  (2  mM  EDTA,  
2%  FBS,  1X  PBS).    Indirect  antibody  labeling  was  completed  via  two  sequential  incubation  
periods  at  4C,  with  one  wash  in  FACS  buffer  following  each  incubation.  Primary  and  secondary  
antibodies,  listed  in  Resources  Table,  have  been  characterized  previously  and  used  to  isolate  
high-­quality  RNA  from  α  cells  (Dorrell  et  al.,  2016).  Appropriate  single  color  compensation  
controls  were  run  alongside  samples.    Prior  to  sorting,  propidium  iodide  (0.05  ug/100,000  cells;;  
BD  Biosciences,  San  Jose,  CA)  was  added  to  samples  for  non-­viable  cell  exclusion.    Flow  
analysis  was  performed  using  an  LSRFortessa  cell  analyzer  (BD  Biosciences),  and  a  FACSAria  
III  cell  sorter  (BD  Biosciences)  was  used  for  FACS.    Analysis  of  flow  cytometry  data  was  
completed  using  FlowJo  10.1.5  (Tree  Star).  
  
Islet  transplantation  and  assessment  of  grafts  
T1D  islets  were  transplanted  into  immunodeficient  10-­12  week  old  NOD-­scid-­IL2rγnull  (NSG)  
male  mice.  Human  islets  from  three  normal  donors  with  an  average  age  of  37  years  (range  from  
20  to  53  years)  and  average  BMI  of  25.1  (range  from  21.7  to  28.2)  were  obtained  through  IIDP  
(Table  S1).  NSG  mice  were  transplanted  beneath  the  renal  capsule  with  500  –  600  normal  or  
T1D  islet  equivalents  (prepared  as  described  above).  Each  set  of  islets  was  transplanted  into  7-­
8  mice.  Islets  were  allowed  to  engraft  for  1  month  and  then  mice  were  randomized  for  an  
additional  1-­month  treatment  with  either  phosphate  buffered  saline  (PBS)  or  exendin-­4  (Ex),  
which  were  administered  using  an  Alzet  minipump  (model  1004  with  a  pump  volume  of  100  µL,  
Durect  Corporation).  Ex-­4  (California  Peptide)  was  reconstituted  in  PBS  without  Ca2+  and  Mg2+  
and  loaded  into  Alzet  pump  at  concentration  of  0.9  mg/mL.  Ex-­4  in  plasma  was  measured  by  
EIA  (Phoenix  Pharmaceuticals)  and  reached  concentration  of  4.4  ±  0.2  ng/mL  (n=8  mice).  
Insulin  secretion  in  transplanted  human  islets  was  assessed  by  intraperitoneal  administration  of  
glucose  (2  g/kg  of  body  weight)  and  arginine  (2  g/kg  of  body  weight)  prior  to  and  after  Ex-­4/PBS  
treatment.  Human  insulin  in  plasma  was  measured  by  species-­specific  radioimmunoassay  
(Millipore).    
  
Immunohistochemical  analysis    
Immunohistochemical  analysis  of  pancreas  was  performed  on  serial  5-­µm  cryosections  from  
multiple  blocks  from  head,  body  and  tail  regions  as  described  (Brissova  et  al.,  2014).  Kidneys  
bearing  islet  transplants  were  collected  and  then  5-­µm  cryosections  from  5-­6  different  depths  of  
each  graft  were  labeled  for  immunofluorescence  as  described  (Brissova  et  al.,  2014).  Primary  
antibodies  to  all  antigens  and  their  working  dilutions  are  listed  in  the  Resources  Table.  The  
antigens  were  visualized  using  appropriate  secondary  antibodies  listed  in  the  Resources  Table.  
Tyramide  Signal  Amplification  (Perkin  Elmer)  was  used  to  visualize  ARX  and  NKX2.2  labeling.  
Digital  images  were  acquired  with  a  Zeiss  LSM510  META  laser  scanning  confocal  microscope  
(Carl  Zeiss).    
  
RNA-­sequencing  
Sorted  α  cells  (5,000-­125,000)  were  added  to  200  μL  lysis/binding  solution  in  the  RNAqueous  
micro-­scale  phenol-­free  total  RNA  isolation  kit  (Ambion).  Trace  DNA  was  removed  with  TURBO  
DNA-­free  (Ambion),  RNA  integrity  was  evaluated  (Agilent  2100  Bioanalyzer;;  control,  8.36±0.22  
RIN,  n=5  donors;;  T1D,  7.97±0.32  RIN,  n=3  donors),  and  high-­integrity  total  RNA  was  amplified  
(Ovation  system;;  NuGen  Technologies)  per  standard  protocol  as  described  previously  (Brissova  
et  al.,  2014).  Amplified  cDNA  was  sheared  to  target  200bp  fragment  size  and  libraries  were  
  prepared  using  NEBNext  DNA  Library  Prep  (New  England  BioLabs).  50bp  Paired  End  (PE)  
sequencing  was  performed  on  an  Illumina  HiSeq  2500  using  traditional  Illumina  methods  
(Malone  and  Oliver,  2011)  to  generate  approximately  50  million  reads  per  sample.  Raw  reads  
were  mapped  to  the  reference  human  genome  hg19  using  TopHat  v2.1  (Trapnell  et  al.,  2009).  
Aligned  reads  were  then  imported  onto  the  Avadis  NGS  analysis  platform  (Strand  life  Sciences)  
and  filtered  based  on  read  quality  followed  by  read  statistics  to  remove  duplicates.  Transcript  
abundance  was  quantified  using  the  TMM  (Trimmed  Mean  of  M-­values)  algorithm  (Dillies  et  al.,  
2012;;  Robinson  and  Oshlack,  2010)  as  the  normalization  method.      
  
Quantification  of  cellular  protein  expression  
Histopathology  reviews  were  conducted  on  the  whole  slide  digital  images.  Protein  expression  of  
nuclear  factors  in  α  and  β  cells  was  quantified  using  MetaMorph  7.1  imaging  software  
(Molecular  Devices)  using  manual  cell  counting  (Brissova  et  al.,  2014)  where  an  average  of  
351±73  α  cells  and  861±141  β  cells  were  counted  per  normal  donor  (n=7),  and  average  of  




Genes  with  normalized  expression  values  less  than  25  were  removed  prior  to  differential  
expression  analysis  between  control  and  T1D  groups.    Fold  change  (cutoff  ≥  ±1.5)  was  
calculated  based  on  p-­value  estimated  by  z-­score  calculations  (cutoff  0.05)  as  determined  by  
Benjamini  Hochberg  false  discovery  rate  (FDR)  correction  of  0.05  (Benjamini  and  Hochberg,  
1995).  Differentially  expressed  genes  were  further  analyzed  through  Ingenuity  Pathway  Analysis  
(IPA,  Qiagen)  (Figure  S4C,  Table  S3)  and  Gene  Ontology  (GO)  analysis  using  DAVID  v6.8  



























  RESOURCES  TABLE    
  
REAGENT  or  RESOURCE   SOURCE   IDENTIFIER  
Antibodies  





Rabbit  anti-­Glucagon  (1:200)   Cell  Signaling   Cat#  2760;;  RRID:  
AB_659831  
Mouse  anti-­Glucagon  (1:500)   Abcam   Cat#  ab10988;;  RRID:  
AB_297642  
Mouse  anti-­Glucagon-­  Pacific  Blue  (1:600;;  flow  
cytometry)  
Sigma-­Aldrich   Cat#  G2654;;  RRID:  
AB_259852  
Rabbit  anti-­Insulin-­647  (1:65)   Cell  Signaling   Cat#  9008  
Guinea  pig  anti-­Insulin  (1:1000)   Dako   Cat#  A0564  
Chicken  anti-­Insulin  (1:10;;  flow  cytometry)   Gallus  Immunotech   Cat#  ABI  
Rabbit  anti-­MAFB  (1:3000)   Gift  from  Roland  Stein,  
Vanderbilt  University  
Cat#  BL1228  
Mouse  anti-­NKX2.2  (1:1000)   Developmental  Studies  
Hybridoma  Bank  
Cat#  74-­5A5;;  RRID:  
AB_531794  
Rabbit  anti-­NKX6.1  (1:2000)   BCBC/Palle  Serup   N/A  
Rabbit  anti-­PDX1  (1:5000)   C.  V.  E.  Wright   N/A  
Goat  anti-­PDX1  (1:5000)   C.  V.  E.  Wright   N/A  
Goat  anti-­Somatostatin  (1:500)   Santa  Cruz   Cat#  sc-­7819;;  RRID:  
AB_2302603  
Mouse  anti-­Somatostatin-­AlexaFluor  488  (1:200;;  flow  
cytometry)  
LS  Bio   Cat#  LS-­C169129-­
100  
Mouse  anti-­HIC3-­2D12  (Hpa3;;  1:200;;  flow  cytometry)   Gift  from  Drs.  Philip  
Streeter  and  Markus  
Grompe  
N/A  
Mouse  anti-­HIC0-­4F9-­Biotin  (Hpi1;;  1:100;;  flow  
cytometry)  
Novus   Cat#  NBP1-­18872B  
RRID:  AB_2126328  
























Goat  anti-­mouse-­PE  (1:1000;;  flow  cytometry)   BD  Biosciences   Cat#  550589  
RRID:  AB_393768  
Streptavidin  BV421  (1:500;;  flow  cytometry)   BD  Biosciences   Cat#  563259  
Biological  Samples  
Human  Pancreatic  Islets  (control  and  T1D)   Integrated  Islet  
Distribution  Program  and  
Rita  Bottino  
  
Human  Pancreatic  Tissue  (control  and  T1D)   Rita  Bottino     
  Chemicals,  Peptides,  and  Recombinant  Proteins  
Propidium  Iodide   BD  Biosciences   Cat#  556463  
Exenatide-­4  (Ex-­4)   California  Peptide   Cat#  507-­77  
L-­Arginine  monohydrochloride   Sigma  Life  Science   Cat#  A6969-­25G;;  
CAS:  001119-­34-­2  
D-­(+)-­Glucose   Sigma  Life  Science   Cat#  G7528-­1KG;;  
CAS:  50-­99-­7  
3-­Isobutyl-­1-­methylxanthine  (IBMX)   Sigma  Life  Science   Cat#  I5879-­1G;;  CAS:  
28822-­58-­4  
(±)-­Epinephrine-­hydrochloride     Sigma-­Aldrich   Cat#  E4642-­5G;;  
CAS:  329-­63-­5  
Potassium  Chloride   Fisher  Scientific   Cat#  BP366-­500;;  
CAS:  7447-­40-­7  
Collagenase  NB1  Premium  Grade   Crescent  Chemical   Cat#  17455.03  
Neutral  Protease  NB1  Premium  Grade   Crescent  Chemical   Cat#  30301.02  
DNase  I   Worthington  Biochemical  
Corporation  
Cat#  LS006333  
RPMI  Medium   Mediatech   99-­595-­CM  
Biocoll-­Separating  Solution,  Density  1.10  g/mL   Cedarlane   Cat#  L6155  
Biocoll-­Separating  Solution,  Density  1.077  g/mL   Cedarlane   Cat#  L6113  
Fetal  Calf  Serum   Life  Technologies   Cat#  16-­140-­071  
Dithizone   Sigma   Cat#  D5130  
CMRL  1066  Medium   Mediatech   Cat#  99-­663-­CV  
Penicillin/Streptomycin  mix   Life  Technologies   Cat#  15140163  
L-­glutamine   Life  Technologies   Cat#  2030-­081  
16%  paraformaldehyde   Electron  Microscopy  
Sciences  
Cat#  15710  
O.C.T.  compound   Fisher  Scientific   Cat#  4585  
Critical  Commercial  Assays  
Insulin  Radioimmunoassay   Millipore   RI-­13K  
Glucagon  Radioimmunoassay   Millipore   GL-­32K  
RNAqueous-­Microkit   Invitrogen  by  Thermo  
Fisher  Scientific  
AM1931  
EIA  ELISA   Phoenix  Pharmaceuticals   EK-­070-­94  
Human-­specific  insulin  radioimmunoassay   Millipore   HI-­14K  
Deposited  Data  
RNA-­seq  data  for  FACS  purified  human  control  and  
T1D  alpha  cells    
NCBI  Gene  Expression  
Omnibus  
GEO:  GSE106148  
Experimental  Models:  Organisms/Strains  
Mouse:  NOD-­scid-­IL2rγnull  (NSG)   Jackson  Laboratory   https://www.jax.org/st
rain/005557  
Oligonucleotides  
18S   Applied  Biosystems   Hs99999901_s1  
ACTB   Applied  Biosystems   Hs99999903_m1  
ARX   Applied  Biosystems   Hs00292465_m1  
GCG   Applied  Biosystems   Hs00174967_m1  
INS   Applied  Biosystems   Hs02741908_m1  
MAFA   Applied  Biosystems   Hs01651425_s1  
MAFB   Applied  Biosystems   Hs00534343_s1  
NKX2.2   Applied  Biosystems   Hs00159616_m1  
  NKX6.1   Applied  Biosystems   Hs00232355_m1  
PDX1   Applied  Biosystems   Hs00236830_m1  
Software  and  Algorithms  
TopHat  (v2.1)   Trapnell,  2009   http://tophat.cbcb.um
d.edu/    
RRID:  SCR_013035  





Trimmed  Mean  of  M-­values  (TMM)  algorithm   Dillies,  2012  
Robinson,  2010  
  
DAVID  (v6.8)   Huang,  2009   http://david.abcc.ncifc
rf.gov/    
RRID:  SCR_001881  
Ingenuity  Pathway  Analysis  (IPA)   Qiagen   RRID:  SCR_008653  
Prism  v.7.0   Graphpad  Software   https://www.graphpad
.com;;    
RRID:  SCR_002798  
MetaMorph  7.1     Molecular  Devices   https://www.molecula
rdevices.com;;  RRID:  
SCR_002368  
Zeiss  LSM  Imaging  Software  (confocal)   Carl  Zeiss   https://www.zeiss.co
m;;  
RRID:  SCR_014344  
Genome  Analysis  Toolkit  (GATK)  HaploTypeCaller  
v3.3  




Zenon  Kit  Alexa  Fluor  488   Invitrogen   Cat#  Z25002  
Zenon  Kit  Pacific  Blue   Invitrogen   Cat#  Z25041  














Figure  S1.  Related  to  Figures  1  and  2.  Composition  and  morphology  in  T1D  islets.  (A)  Schematic  of  islet  isolation  
and  tissue  procurement  from  the  same  pancreas.  Prior  to  islet  isolation,  multiple  cross-­sectional  slices  of  pancreas  with  2-­
3  mm  thickness  were  obtained  from  the  head,  body  and  tail.  Pancreatic  slices  were  further  divided  into  four  quadrants  (A,  
B,  C,  D)  and  processed  for  histology.  (B)  Pancreatic  islets  procured  from  a  12-­year-­old  individual  with  3-­year  T1D  duration  
(donor  #1).  (C)  Endocrine  cell  populations  in  dispersed  isolated  islets  from  3  donors  (#1,4,5)  with  recent-­onset  T1D  
contained  10.8±0.5%  β  cells,  77.1±6.3%  α  cells,  and  12.0±5.9%  δ  cells.  The  donor  with  longstanding  T1D  (donor  #8)  had  
0%  β  cells,  95%  α  cells,  and  5%  δ  cells.  For  comparison,  islets  from  normal  individuals  (n=28)  with  average  age  of  36±2  
years  (range  16  –  63  years)  assessed  by  this  approach  had  53.4±2.6%  β  cells,  38.5±2.7%  α  cells,  and  7.5±0.9%  δ  cells  
(Blodgett  et  al.,  2015).  (D)  Morphology  of  T1D  islets  in  the  native  pancreas.  On  average  250  islets  from  pancreatic  head,  
body  and  tail  of  each  T1D  donor  were  analyzed  for  the  presence  of  β  cells.  An  islet  was  categorized  as  insulin+  even  if  it  
had  only  one  insulin-­positive  cell.  The  number  of  insulin+  islets  varied  in  4  donors  (#1,3,4,5)  with  recent-­onset  T1D  
(17.8±15.5%),  but  no  insulin+  islets  were  found  in  the  pancreatic  sections  of  our  longstanding  cases  (donors  #6,7,8).  If  
donors  had  insulin+  islets,  representative  islets  are  displayed  in  row  1.  INS–insulin,  GCG–glucagon,  SOM–somatostatin.  
Scale  bar  is  50  µm.  
  
Figure  S2.  Related  to  Figure  1.  Expression  pattern  of  PDX1,  NKX6.1,  and  NKX2.2  in  T1D  β  cells.  Expression  of  β  
cell-­enriched  transcription  factors  in  the  native  pancreatic  tissue  from  donors  with  recent-­onset  T1D  (donors  #1,5)  was  
compared  to  58-­year-­old  donor  with  31  years  of  T1D  duration  (donor  #8)  and  controls.  INS–insulin,  GCG–glucagon,  
SOM–somatostatin.  Regions  denoted  by  the  dashed  line  in  panels  E’–  G’  are  displayed  in  panels  E  –  G  in  Figure  1,  
respectively.  Scale  bar  in  E’  is  50  µm  and  also  corresponds  to  panels  F’  and  G’.  
  
Figure  S3.  Related  to  Figure  2.  Expression  pattern  of  MAFB,  ARX,  and  NKX6.1  in  T1D  α  cells.  Expression  of  α  cell-­
enriched  transcription  factors  in  the  native  pancreatic  tissue  from  donors  with  recent-­onset  T1D  (donors  #1,2,5)  was  
compared  to  58-­year-­old  donor  with  31  years  of  T1D  duration  and  controls  (donor  #8).  GCG–glucagon,  SOM–
somatostatin.  Regions  denoted  by  the  dashed  line  in  panels  E’–G’  are  displayed  in  panels  E–G  in  Figure  2,  respectively.  






Figure  S4.  Related  to  Figure  4.  Transcriptome  analysis  of  purified  human  α  cells  by  RNA-­sequencing.  (A)  Gating  
strategy  for  sorting  of  dispersed  human  islet  cells  by  Fluorescence  Activated  Cell  Sorting  (FACS).  Cell  debris  was  
excluded  by  forward  scatter  (FSC)  and  side  scatter  (SSC),  single  cells  were  identified  by  SSC-­H  v.  SSC-­A  plot,  and  non-­
viable  cells  were  excluded  using  Propidium  Iodide  (PI).  The  α  cell  population  was  isolated  based  on  double  positivity  for  
HIC3-­2D12  (Hpa3)  and  HIC0-­4F9  (Hpi1)  antibodies.  (B)  Volcano  plot  displays  transcripts  differentially  expressed  between  
control  and  T1D  samples  (donors  #3,6,7)  that  reached  statistical  significance  (upregulation:  red;;  downregulation:  green).  
Differential  expression  between  the  two  sample  sets  was  calculated  on  the  basis  of  FC  (≥1.5)  with  a  <0.05  p-­value  cut-­off  
for  calculated  z-­score.  (C)  Graph  represents  the  top  20  most  significantly  (z-­score  >2  or  <-­2)  altered  canonical  pathways  
identified  by  Ingenuity  Pathway  Analysis  (IPA)  with  corresponding  p-­value  depicted  on  graph  bar.  Pathways  with  affiliated  
Ensembl  Gene  Stable  IDs  are  listed  in  Table  S3.  (D)  Bar  graph  highlights  the  percentage  of  up-­  and  down-­regulated  
genes  (with  corresponding  gene  number  displayed  within  bar)  in  the  top  20  significant  biological  processes,  cellular  
components,  and  molecular  functions  identified  by  Gene  Ontology  (GO)  term  analysis.  Corresponding  p-­values,  Ensembl  
Gene  Stable  IDs  and  process  GO  accession  numbers  are  listed  in  Table  S4.  
  
Table  S1.  Related  to  Figures  1-­4.  Demographic  information  of  normal  donors  
  
N/A  –  not  available;;  IIDP  –  Integrated  Islet  Distribution  Program  
  
Donors   Age  (years)  
Ethnicity/  









7   Caucasian   M   26.8   Respiratory  arrest   Rita  Bottino  
8   Caucasian   F   16.1   Intracerebral  hemorrhage   Rita  Bottino  
8   African  American   M   17.2   Anoxia   Rita  Bottino  
9   Caucasian   M   15.5   Head  Trauma   Rita  Bottino  
11   African  American   M   18.3   Anoxia   Rita  Bottino  
19   Caucasian   M   20.1   Head  Trauma   Rita  Bottino  





20   African  American   M   21.7   Head  Trauma   IIDP  
39   N/A   F   28.2   N/A   IIDP  
53  
Native  Hawaiian  
or  Other  Pacific  
Islander  




11   Caucasian   M   22.7   Anoxia   Rita  Bottino  
20   Hispanic/  Latino   F   24.6   Anoxia   IIDP  




8   African  American   M   17.2   Anoxia   Rita  Bottino  
10   Caucasian   M   19.3   Head  Trauma   Rita  Bottino  
19   Caucasian   M   20.1   Head  Trauma   Rita  Bottino  
19   Caucasian   M   21.2   Anoxia   Rita  Bottino  
20   Hispanic/  Latino   M   19.4   Head  Trauma   Rita  Bottino  
24   Caucasian   M   35.5   Head  Trauma   Rita  Bottino  




26   Hispanic/Latino   F   35.9   Anoxia   IIDP  
35   Caucasian   F   23.6   Anoxia   IIDP  
49   Caucasian   F   31.6   Stroke   IIDP  
50   African  American   M   30.2   Stroke   IIDP  
55   Caucasian   M   27.8   Stroke   IIDP  
Table  S2.  Related  to  Figures  1-­  4  and  Table  1.  DNA  sequencing  of  T1D  donors  for  variants  associated  with  monogenic  
diabetes      
Donor   Gene   Chr   Transcript   Nucleotide   Amino  Acid  Change   dbSNP  ID   MAF   POLY  Score  
1  
AKT2   19   NM_001626.5   c.*9C>T   -­   rs79275829   0.004   0  
CYP27B1   12   NM_000785.3   c.963+2T>G   -­   -­   0   0  
CYP27B1   12   NM_000785.3   c.963+7T>G   -­   -­   0   0  
FOXP3   X   NM_014009.3   c.403A>C   p.Thr135Pro   -­   0   0  
IFIH1   2   NM_022168.3   c.1641+1G>C   -­   rs35337543   0.007   0  
SIRT1   10   NM_012238.4   c.110C>T   p.Pro37Leu   -­   0   0.013  
GLP1R   6   NM_002062.3   c.1347G>A   p.Ala449Ala   rs201020486   0   0  
2  
AIRE   21   NM_000383.3   c.1411C>T   p.Arg471Cys   rs74203920   0.006   0.997  
ALMS1   2   NM_015120.4   c.69_77del   p.Glu27_Glu29del   -­   0   0  
HSD11B1   1   NM_005525.3   c.219+6G>A   -­   rs202219444   0   0  
LRBA   4   NM_006726.4   c.1536A>G   p.Ser512Ser   -­   0   0  
POMC   2   NM_001035256.1   c.706C>G   p.Arg236Gly   rs28932472   0.004   1  
PTPN22   1   NM_015967.5   c.1508A>G   p.Tyr503Cys   rs371916399   0   0.004  
TBC1D4   13   NM_014832.3   c.2913A>T   p.Gly971Gly   rs184774790   0   0  
3  
BBS5   2   NM_152384.2   c.620G>A   p.Arg207His   rs35487251   0.006   0.833  
BLM   15   NM_000057.3   c.2119C>T   p.Pro707Ser   rs146077918   0.001   0.018  
EIF2AK3   2   NM_004836.5   c.-­201A>G   -­   rs144057685   0.005   0  
HFE   6   NM_000410.3   c.845G>A   p.Cys282Tyr   rs1800562   0.02   0  
HNF4A   20   NM_175914.4   c.1314C>G   p.Leu438Leu   -­   0   0  
PIK3R1   5   NM_181523.2   c.1176C>T   p.Phe392Phe   rs3730090   0.308   0  
4  
ALMS1   2   NM_015120.4   c.12278G>A   p.Arg4093His   -­   0   0  
FBN1   15   NM_000138.4   c.3294C>T   p.Asp1098Asp   rs140587   0.008   0  
GLP1R   6   NM_002062.3   c.59G>A   p.Arg20Lys   rs10305421   0.007   0.643  
IFIH1   2   NM_022168.3   c.1075G>C   p.Val359Leu   -­   0   0.996  
MKS1   17   NM_017777.3   c.1528C>T   p.Arg510Trp   -­   0   0.976  
Chr  –  Chromosome,  MAF  –  Minor  allele  frequency;;  DNA  isolated  from  pancreatic  samples  of  T1D  donors  was  subjected  to  DNA  sequencing  covering  
coding  regions  and  splice  junctions  of  148  genes  associated  with  monogenic  diabetes.    
  
5  
BLM   15   NM_000057.3   c.2268A>G   p.Lys756Lys   rs146013879   0.001   0  
CLEC16A   16   NM_015226.2   c.2945G>A   p.Ser982Asn   rs72650689   0.004   0.967  
HFE   6   NM_000410.3   c.187C>G   p.His63Asp   rs1799945   0.084   0  
LRBA   4   NM_006726.4   c.7597A>C   p.Thr2533Pro   rs62346982   0.003   0.167  
KCNK16   6   NM_032115.3   c.165G>A   p.Leu55Leu   rs138076469   0.002   0  
LMNA   1   NM_005572.3   c.612G>A   p.Leu204Leu   rs12117552   0.004   0  
6  
ABCC8   11   NM_000352.4   c.-­430C>T     -­   -­   0   0  
BBS2   16   NM_031885.3   c.155T>A   p.Val52Asp   -­   0   0.016  
EIF2AK3   2   NM_004836.5   c.-­201A>G     -­   rs144057685   0.005   0  
MKKS   20   NM_018848.3   c.1015A>G   p.Ile339Val   rs137853909   0.001   0.008  
NTRK2   9   NM_006180.4   c.483T>G   p.Thr161Thr   rs199849633   0   0  
VPS13B   8   NM_017890.4   c.8978A>G   p.Asn2993Ser   rs28940272   0.002   0.997  
7  
ABCC8   11   NM_000352.4   c.2176G>A   p.Ala726Thr   rs138687850   0.001   0.02634  
AKT2   19   NM_001626.5   c.1110G>T   p.Pro370Pro   rs41309435   0.001   0  
CFTR   7   NM_000492.3   c.1521_1523del   p.Phe508del   rs199826652   0.006   0  
LRBA   4   NM_006726.4   c.217-­10del   -­     -­   0   0  
VPS13B   8   NM_017890.4   c.1832G>A   p.Arg611Lys   rs61754109   0   0.02634  
8  
AKT2   19   NM_001626.5   c.945G>A   p.Glu315Glu   rs150000674   0.002   0  
CYP27B1   12   NM_000785.3   c.963+2T>G   -­   -­   0   0  
CYP27B1   12   NM_000785.3   c.963+7T>G   -­   -­   0   0  
FXN   9   NM_000144.4   c.-­7G>A   -­   rs145006100   0.011   0  
IFIH1   2   NM_022168.3   c.1641+1G>C   -­   rs35337543   0.007   0  
SUPPLEMENTAL  REFERENCES  
  
Aamodt,  K.I.  et  al.,  2016.  Development  of  a  reliable  automated  screening  system  to  identify  
small  molecules  and  biologics  that  promote  human  β-­cell  regeneration.  American  journal  of  
physiology  Endocrinology  and  metabolism,  311(5),  pp.E859–E868.  
Alkorta-­Aranburu,  G.  et  al.,  2016.  Improved  molecular  diagnosis  of  patients  with  neonatal  
diabetes  using  a  combined  next-­generation  sequencing  and  MS-­MLPA  approach.  Journal  of  
pediatric  endocrinology  &  metabolism  :  JPEM,  29(5),  pp.523–531.  
Benjamini,  Y.  &  Hochberg,  Y.,  1995.  A  direct  approach  to  false  discovery  rates.  J.  Royal  Stat.  
Soc.,  Ser.  B,  57(1),  pp.289–300.  
Blodgett,  D.M.  et  al.,  2015.  Novel  Observations  From  Next-­Generation  RNA  Sequencing  of  
Highly  Purified  Human  Adult  and  Fetal  Islet  Cell  Subsets.  Diabetes,  64(9),  pp.3172–3181.  
Brissova,  M.  et  al.,  2014.  Islet  microenvironment,  modulated  by  vascular  endothelial  growth  
factor-­A  signaling,  promotes  β  cell  regeneration.  Cell  metabolism,  19(3),  pp.498–511.  
Dillies,  M.-­A.  et  al.,  2012.  A  comprehensive  evaluation  of  normalization  methods  for  Illumina  
high-­throughput  RNA  sequencing  data  analysis.  Briefings  in  bioinformatics.  
Dorrell,  C.  et  al.,  2016.  Human  islets  contain  four  distinct  subtypes  of  β  cells.  Nature  
communications,  7,  p.11756.  
Huang,  D.W.  et  al.,  2009.  Extracting  biological  meaning  from  large  gene  lists  with  DAVID.  
Current  protocols  in  bioinformatics,  Chapter  13,  p.Unit  13.11.  
Kayton,  N.S.  et  al.,  2015.  Human  islet  preparations  distributed  for  research  exhibit  a  variety  of  
insulin-­secretory  profiles.  American  journal  of  physiology  Endocrinology  and  metabolism,  
308(7),  pp.E592–602.  
Malone,  J.H.  &  Oliver,  B.,  2011.  Microarrays,  deep  sequencing  and  the  true  measure  of  the  
transcriptome.  BMC  biology,  9,  p.34.  
Robinson,  M.D.  &  Oshlack,  A.,  2010.  A  scaling  normalization  method  for  differential  expression  
analysis  of  RNA-­seq  data.  Genome  biology,  11(3),  p.R25.  
Trapnell,  C.,  Pachter,  L.  &  Salzberg,  S.L.,  2009.  TopHat:  discovering  splice  junctions  with  RNA-­
Seq.  Bioinformatics  (Oxford,  England),  25(9),  pp.1105–1111.  
  
